The UK government reported on October 21 that the average setup time for commercial clinical trials fell to 100 days in the three months through March 2026, compared with 153 days in the equivalent period a year earlier. The measure covers how quickly trial sites become ready, not how long an entire study takes.

All 24 commercial trials in that three-month group were set up within 150 days. The government also says every study receiving combined Medicines and Healthcare products Regulatory Agency and research-ethics approval in September was approved within 60 days.

Examples cited include a group B streptococcus vaccine study that moved into operation in less than 150 days and a Moderna study that recruited 2,500 volunteers in nine weeks. Those examples describe process and recruitment milestones; they do not establish that an experimental treatment is effective or approved for routine use.

Faster setup can give patients earlier opportunities to join research and can improve predictability for sponsors. Officials and industry representatives nevertheless said recruitment, delivery across multiple sites and broad patient participation still require continued work. Setup speed is one part of clinical research performance, not a substitute for safety and outcome evidence.